Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GALR2 | O43603 | 2/20 | 0.46 |
| ▸ | GALR1 | P47211 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551893 | 1.00 | HTT (0.49) | HTTGALR2GALR1ALDH1A1USP30 | |
| SCHEMBL20551540 | 0.92 | TP53 (0.50) | HTTALDH1A1USP30MAPTTSHR | |
| SCHEMBL21750810 | 0.92 | TP53 (0.50) | HTTALDH1A1USP30MAPTTSHR | |
| SCHEMBL21750727 | 0.89 | USP30 (0.45) | USP30MAPTHPGDSPRMT5MMP13 | |
| SCHEMBL21750806 | 0.84 | USP30 (0.46) | USP30HPGDSACP1PRMT5APLNR | |
| SCHEMBL20552124 | 0.82 | MAPT (0.52) | HTTALDH1A1MAPTNPSR1KDM4E | |
| SCHEMBL25086948 | 0.78 | ALDH1A1 (0.45) | HTTALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL20551464 | 0.78 | PDE10A (0.49) | GALR2GALR1ALDH1A1MAPT | |
| SCHEMBL25087215 | 0.78 | GRM5 (0.43) | GALR2ALDH1A1MAPTNPSR1ACP1 | |
| SCHEMBL20551961 | 0.77 | ADORA3 (0.45) | GALR2GALR1MAPTACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-23 | — | — | US | disclosed |
| EP-3825310-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2025-11-12 | — | — | EP | disclosed |
| US-20240391898-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-11-28 | — | — | US | disclosed |
| CN-112279833-B | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy | 意大利学院科技基金会 | 2024-04-16 | — | — | CN | disclosed |
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-04-09 | — | — | US | disclosed |
| CN-110799505-B | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy | 意大利学院科技基金会 | 2022-08-30 | — | — | CN | disclosed |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2022-08-04 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-12-14 | — | — | US | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3619202-B1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2021-06-30 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825310-A1 | TRISUBSTITUTED PYRIMIDINE COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, RETINAL DISORDERS, AND CARDIOMYOPATHIES | Fondazione Istituto Italiano di Tecnologia (IT) | 2021-05-26 | — | — | EP | disclosed |
| CN-112279833-A | Tri-substituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy | 意大利学院科技基金会 | 2021-01-29 | — | — | CN | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-02-27 | — | — | US | disclosed |
| CN-110799505-A | Tri-substituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders and cardiomyopathy | 意大利学院科技基金会 | 2020-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952366-B2 | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases | CDC42, RHOA, TNK2 | HTT 2889/4885GALR2 3164/4885GALR1 2331/4885 |
| US-12503456-B2 | Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors | TNK2, CDC42, CDC42BPA | HTT 3789/4885GALR2 3930/4885GALR1 3310/4885 |
| US-20200062733-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | HTT 3502/4885GALR2 1257/4885GALR1 1048/4885 |
| US-20240391898-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | HTT 3502/4885GALR2 1257/4885GALR1 1048/4885 |
| US-11198682-B2 | Substituted pyrimidines as inhibitors for a Rho family of GTP-ases | CDC42, TNK2, ARHGEF1 | HTT 3174/4885GALR2 3999/4885GALR1 3352/4885 |
| US-20220242848-A1 | Compounds and Compositions for the Treatment of Cancer, Retinal Disorders, and Cardiomyopathies | CDC42, RHOA, RHOT2 | HTT 3502/4885GALR2 1257/4885GALR1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.